SEZI.ST

Senzime AB (publ) [SEZI.ST] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SEZI.ST Stock Summary

Earnings have grown 27.81% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

SEZI.ST has less than 1 year of cash runway

Top 10 Correlated ETFs

SEZI.ST

Top 10 Correlated Stocks

SEZI.ST

In the News

SEZI.ST Financial details

Company Rating

Buy

Market Cap

346.78M

Income

-142.97M

Revenue

18.96M

Book val./share

4.31

Cash/share

1.02

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

18 Jul 2023

P/E

-2.14

Forward P/E

PEG

-0.36

P/S

18.29

P/B

0.97

P/C

4.12

P/FCF

-2.16

Quick Ratio

4.54

Current Ratio

6.64

Debt / Equity

0.04

LT Debt / Equity

0.03

EPS (TTM)

-2.07

EPS next Y

EPS next Q

EPS this Y

53.08%

EPS next Y

EPS next 5Y

EPS last 5Y

28.41%

Revenue last 5Y

34.28%

Revenue Q/Q

60.18%

EPS Q/Q

40%

SMA20

-20%

SMA50

-33.33%

SMA100

-63.64%

Inst Own

Inst Trans

ROA

-39%

ROE

-54%

ROC

-0.42%

Gross Margin

-13%

Oper. Margin

-783%

Profit Margin

-754%

Payout

Shs Outstand

82.57M

Shs Float

47.72M

Target Price

52W Range

3.595-18.76

52W High

-76.67%

52W Low

+40%

RSI

Rel Volume

0.62

Avg Volume

108.27K

Volume

67.13K

Perf Week

-5.83%

Perf Month

-17.65%

Perf Quarter

-63.73%

Perf Half Y

-63.67%

Beta

0.588781

Volatility

0.18%, 0.5%

Prev Close

-2.78%

Price

4.2

Change

11.26%

SEZI.ST Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0.07	0.13	0.16	0.17	0.21
Net income per share	-0.57	-0.66	-0.83	-1.3	-1.99
Operating cash flow per share	-0.4	-0.53	-0.67	-1.28	-2.05
Free cash flow per share	-0.61	-0.61	-0.68	-1.33	-2.13
Cash per share	0.73	0.61	2.81	1.18	0.39
Book value per share	3.74	3.22	4.06	2.38	3.93
Tangible book value per share	0.18	0.26	2.62	1.21	0.28
Share holders equity per share	3.74	3.22	4.06	2.38	3.93
Interest debt per share	0	0	0.04	0.03	0.2
Market cap	342.93M	924.46M	1.37B	1.44B	715.58M
Enterprise value	310.26M	893.56M	1.21B	1.37B	702.58M
P/E ratio	-13.38	-27.45	-28.82	-17.59	-5.39
Price to sales ratio	106.7	137.75	146.47	131.57	50.99
POCF ratio	-19.34	-34.07	-35.67	-17.76	-5.23
PFCF ratio	-12.62	-29.92	-35.37	-17.14	-5.04
P/B Ratio	2.05	5.65	5.91	9.59	2.73
PTB ratio	2.05	5.65	5.91	9.59	2.73
EV to sales	96.53	133.15	129.55	124.9	50.06
Enterprise value over EBITDA	-14.59	-37.29	-33.17	-18.72	-5.94
EV to operating cash flow	-17.5	-32.93	-31.55	-16.86	-5.14
EV to free cash flow	-11.42	-28.92	-31.29	-16.27	-4.95
Earnings yield	-0.07	-0.04	-0.03	-0.06	-0.19
Free cash flow yield	-0.08	-0.03	-0.03	-0.06	-0.2
Debt to equity	0	0	0.01	0.01	0.05
Debt to assets	0	0	0.01	0.01	0.04
Net debt to EBITDA	1.54	1.29	4.33	1	0.11
Current ratio	3.68	5.05	12.04	7.98	2.69
Interest coverage	-13.38K	-12.14K	-400.54	-1.07K	-311.41
Income quality	0.66	0.74	0.78	0.97	1.02
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.48	1.59	3.34	2.57	3.16
Research and developement to revenue	0	0	0.88	1.14	1.39
Intangibles to total assets	0.81	0.8	0.32	0.42	0.75
Capex to operating cash flow	0.53	0.14	0.01	0.04	0.04
Capex to revenue	-2.94	-0.56	-0.04	-0.27	-0.36
Capex to depreciation	-1.72	-0.3	-0.03	-0.27	-0.33
Stock based compensation to revenue	0	0	0	0	0
Graham number	6.94	6.93	8.72	8.33	13.27
ROIC	-0.2	-0.27	0.71	-3.92	-0.5
Return on tangible assets	-0.67	-0.91	-0.27	-0.82	-1.67
Graham Net	0.08	0.16	2.36	0.87	-0.36
Working capital	27.51M	29.72M	159.41M	83.58M	37.18M
Tangible asset value	8.21M	13.12M	149.18M	76.42M	18.58M
Net current asset value	8.03M	13M	146.31M	71.52M	-1.58M
Invested capital	0	0	0.01	0.01	0.05
Average receivables	0	0	0	0	0
Average payables	3.64M	3.87M	3.83M	4.33M	5.63M
Average inventory	1.01M	1.7M	3.19M	6.39M	15.24M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	207.34	70.58	99.91	90.45	144.94
Days of inventory on hand	41.55	58.33	83.65	202.75	428.83
Receivables turnover	0	0	0	0	0
Payables turnover	1.76	5.17	3.65	4.04	2.52
Inventory turnover	8.78	6.26	4.36	1.8	0.85
ROE	-0.15	-0.21	-0.21	-0.55	-0.51
Capex per share	-0.21	-0.07	-0.01	-0.05	-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	0.04	0.05	0.05	0.07	0.1
Net income per share	-0.32	-0.62	-0.73	-0.3	-0.42
Operating cash flow per share	-0.26	-0.36	-0.96	-0.44	-0.46
Free cash flow per share	-0.29	-0.39	-0.98	-0.46	-0.49
Cash per share	0.89	1.94	0.82	0.39	1.02
Book value per share	2.07	2.84	4.25	3.93	4.31
Tangible book value per share	2.07	2.84	4.25	0.28	4.31
Share holders equity per share	2.07	2.84	4.25	3.93	4.31
Interest debt per share	0.02	0.03	0.5	-0.11	0.17
Market cap	1.28B	1.11B	603.69M	715.58M	428.94M
Enterprise value	1.22B	982.88M	559.97M	702.58M	367.38M
P/E ratio	-15.58	-6.86	-2.91	-8.99	-3.48
Price to sales ratio	542.11	325.42	162.28	157.27	58.86
POCF ratio	-76.86	-47.69	-8.88	-24.31	-12.91
PFCF ratio	-69.8	-43.84	-8.68	-23.34	-12.16
P/B Ratio	9.78	5.98	2	2.73	1.37
PTB ratio	9.78	5.98	2	2.73	1.37
EV to sales	518.83	288.83	150.53	154.41	50.41
Enterprise value over EBITDA	-67.49	-25.85	-22.64	-18.74	-13.88
EV to operating cash flow	-73.56	-42.33	-8.24	-23.87	-11.05
EV to free cash flow	-66.8	-38.91	-8.05	-22.92	-10.41
Earnings yield	-0.02	-0.04	-0.09	-0.03	-0.07
Free cash flow yield	-0.01	-0.02	-0.12	-0.04	-0.08
Debt to equity	0.01	0.01	0.05	0.05	0.04
Debt to assets	0.01	0.01	0.03	0.04	0.03
Net debt to EBITDA	3.03	3.28	1.77	0.35	2.33
Current ratio	6.59	5.31	2.68	2.69	6.64
Interest coverage	-1.05K	-2.72K	-1.59	2.12	-117.25
Income quality	0.79	0.57	2.07	0.75	1.06
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.99	6.83	2.21	1.79	1.55
Research and developement to revenue	1.41	1.29	1.42	1.42	0.68
Intangibles to total assets	0.47	0.32	0.8	0.75	0.65
Capex to operating cash flow	0.1	0.09	0.02	0.04	0.06
Capex to revenue	-0.71	-0.6	-0.42	-0.27	-0.28
Capex to depreciation	-0.6	-0.71	-0.19	-0.71	-0.41
Stock based compensation to revenue	0	0	0	0	0
Graham number	3.88	6.3	8.37	5.14	6.41
ROIC	-0.54	1.12	-0.07	-0.17	-0.14
Return on tangible assets	-0.25	-0.26	-0.46	-0.25	-0.24
Graham Net	0.63	1.44	-2.88	-0.36	0.43
Working capital	63.71M	118.46M	57.75M	37.18M	91.75M
Tangible asset value	58.01M	113.88M	-160.05M	18.58M	73.4M
Net current asset value	51.9M	106.46M	-181.89M	-1.58M	54.49M
Invested capital	0.01	0.01	0.05	0.05	0.04
Average receivables	3.65M	2.59M	3.24M	1.83M	0
Average payables	3.68M	5.54M	5.98M	5.81M	5.71M
Average inventory	9.22M	9.5M	13.73M	19.86M	21.91M
Days sales outstanding	90.46	74.37	88.67	0	0
Days payables outstanding	89.92	162.7	46.93	261.25	58.37
Days of inventory on hand	252.2	199.19	197.36	772.98	315.15
Receivables turnover	0.99	1.21	1.02	0	0
Payables turnover	1	0.55	1.92	0.34	1.54
Inventory turnover	0.36	0.45	0.46	0.12	0.29
ROE	-0.16	-0.22	-0.17	-0.08	-0.1
Capex per share	-0.03	-0.03	-0.02	-0.02	-0.03

SEZI.ST Frequently Asked Questions

What is Senzime AB (publ) stock symbol ?

Senzime AB (publ) is a SE stock and trading under the symbol SEZI.ST

What is Senzime AB (publ) stock quote today ?

Senzime AB (publ) stock price is $4.2 today.

Is Senzime AB (publ) stock public?

Yes, Senzime AB (publ) is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 108.27K
Market Capitalization 346.78M
Employee 45
CEO Mr. Philip Siberg
Headquarters Uppsala,SE
IPO Date 2008-06-18
Website https://senzime.com

Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.